Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct 7;14(1):153.
doi: 10.1186/s12916-016-0700-9.

Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial

Mark Ng Tang Fui  1   2 , Luke A Prendergast  1   3 , Philippe Dupuis  1   2 , Manjri Raval  2 , Boyd J Strauss  4 , Jeffrey D Zajac  1   2 , Mathis Grossmann  5   6
Affiliations
Randomized Controlled Trial

Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial

Mark Ng Tang Fui et al. BMC Med. .

Abstract

Background: Whether testosterone treatment has benefits on body composition over and above caloric restriction in men is unknown. We hypothesised that testosterone treatment augments diet-induced loss of fat mass and prevents loss of muscle mass.

Methods: We conducted a randomised double-blind, parallel, placebo controlled trial at a tertiary referral centre. A total of 100 obese men (body mass index ≥ 30 kg/m2) with a total testosterone level of or below 12 nmol/L and a median age of 53 years (interquartile range 47-60) receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of 10-weekly intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). The main outcome measures were the between-group difference in fat and lean mass by dual-energy X-ray absorptiometry, and visceral fat area (computed tomography).

Results: A total of 82 men completed the study. At study end, compared to controls, cases had greater reductions in fat mass, with a mean adjusted between-group difference (MAD) of -2.9 kg (-5.7 to -0.2; P = 0.04), and in visceral fat (MAD -2678 mm2; -5180 to -176; P = 0.04). Although both groups lost the same lean mass following VLED (cases -3.9 kg (-5.3 to -2.6); controls -4.8 kg (-6.2 to -3.5), P = 0.36), cases regained lean mass (3.3 kg (1.9 to 4.7), P < 0.001) during weight maintenance, in contrast to controls (0.8 kg (-0.7 to 2.3), P = 0.29) so that, at study end, cases had an attenuated reduction in lean mass compared to controls (MAD 3.4 kg (1.3 to 5.5), P = 0.002).

Conclusions: While dieting men receiving placebo lost both fat and lean mass, the weight loss with testosterone treatment was almost exclusively due to loss of body fat.

Trial registration: clinicaltrials.gov, identifier NCT01616732 , registration date: June 8, 2012.

Keywords: Body composition; Caloric restriction; Obesity; Testosterone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Trial profile. Shown is study enrolment and follow-up. The most common reason for non-completion was failure to attend visits. Serious adverse events are detailed in Table 4. BMI body mass index, CKD chronic kidney disease, CCF congestive cardiac failure, OSA obstructive sleep apnoea, VLED very low energy diet
See this image and copyright information in PMC

References

    1. Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship among body fat percentage, body mass index, and all-cause mortality. A cohort study relationship among body fat percentage, body mass. Ann Intern Med. 2016;164:532–41. doi: 10.7326/M15-1181. - DOI - PubMed
    1. Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutr Rev. 2010;68:375–88. doi: 10.1111/j.1753-4887.2010.00298.x. - DOI - PubMed
    1. Tajar A, Forti G, O’Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95:1810–8. doi: 10.1210/jc.2009-1796. - DOI - PubMed
    1. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430–9. doi: 10.1210/jc.2010-3012. - DOI - PMC - PubMed
    1. Veldhuis J, Yang R, Roelfsema F, Takahashi P. Proinflammatory cytokine infusion attenuates LH’s feedforward on testosterone secretion: modulation by age. J Clin Endocrinol Metab. 2016;101:539–49. doi: 10.1210/jc.2015-3611. - DOI - PMC - PubMed

Publication types

Associated data